SCHEMBL15328481

SCHEMBL15328481

Nc1ncc(Cc2cc(CC(N)C(=O)O)ccc2O)s1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC7A5 Q01650 7/20 0.60
HSD17B10 Q99714 3/20 0.52
USP2 O75604 3/20 0.52
KDM4E B2RXH2 2/20 0.52
ALOX15 P16050 2/20 0.52
RECQL P46063 2/20 0.52
HIF1A Q16665 2/20 0.52
TDP1 Q9NUW8 2/20 0.52
PTGS1 P23219 2/20 0.52
EGFR P00533 1/20 0.52
LCK P06239 1/20 0.52
FYN P06241 1/20 0.52
ADORA3 P0DMS8 1/20 0.52
HTR2A P28223 1/20 0.52
PTGS2 P35354 1/20 0.52
TSHR P16473 1/20 0.52
PKM P14618 3/20 0.43
EPHX2 P34913 1/20 0.42
THRB P10828 3/20 0.40
THRA P10827 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15328477 1.00 SLC7A5 (0.60) SLC7A5HSD17B10USP2KDM4EALOX15
SCHEMBL17082311 0.82 SLC7A5 (0.53) SLC7A5HSD17B10USP2KDM4EALOX15
SCHEMBL10074960 0.77 SMN1; SMN2 (0.50) SLC7A5HSD17B10USP2KDM4EALOX15
SCHEMBL7425388 0.77 SMN1; SMN2 (0.50) SLC7A5HSD17B10USP2KDM4EALOX15
SCHEMBL10074961 0.77 SMN1; SMN2 (0.50) SLC7A5HSD17B10USP2KDM4EALOX15
SCHEMBL5324730 0.76 SLC7A5 (1.00) SLC7A5HSD17B10USP2KDM4EALOX15
SCHEMBL11077965 0.76 SLC7A5 (0.84) SLC7A5HSD17B10USP2KDM4EALOX15
SCHEMBL2299795 0.76 SLC7A5 (1.00) SLC7A5HSD17B10USP2KDM4EALOX15
SCHEMBL5321753 0.74 SLC7A5 (0.71) SLC7A5HSD17B10USP2KDM4EALOX15
SCHEMBL20912657 0.74 SLC7A5 (0.71) SLC7A5HSD17B10USP2KDM4EALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9169295-B2 Macrocycles and macrocycle stabilized peptides BRISTOL-MYERS SQUIBB COMPANY (US) 2015-10-27 US disclosed
EP-2627662-B1 METHODS FOR PREPARING MACROCYCLES AND MACROCYCLE STABILIZED PEPTIDES BRISTOL MYERS SQUIBB CO (US) 2015-09-16 EP disclosed
US-20130281657-A1 MACROCYCLES AND MACROCYCLE STABILIZED PEPTIDES BRISTOL-MYERS SQUIBB COMPANY (US) 2013-10-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130281657-A1 MACROCYCLES AND MACROCYCLE STABILIZED PEPTIDES PTMS, VIP, MTPN SLC7A5 96/4885HSD17B10 3722/4885USP2 3830/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.